

# NIDA CTN Research Updates: Treatments for Stimulant Use Disorders

**Geetha Subramaniam, MD DLFAPA, DFAACAP**

ASAM 55th Annual Conference  
April 2024



# Disclosures

## Introduction

- Geetha Subramaniam (Chair)
- No Disclosures

# Learning Objectives (for the Session)

Upon completion of the session, the participant will be able to:

- ✓ demonstrate an increased knowledge of pharmacotherapy options for the management of stimulant use disorders.
- ✓ discover the mechanisms and utility of brain stimulation techniques including transcranial magnetic stimulation in the management of stimulant use disorders.
- ✓ articulate the value of artificial intelligence techniques in evaluating and repurposing existing medications in the management of stimulant use disorders.

# Agenda

- Background and Introductions
- Pharmacological treatments for stimulant use disorders –  
Madhukar Trivedi, MD
- Neuromodulation in the management of stimulant use  
disorders – Kathleen Brady, MD
- Repurposing of medications using AI and other clinical  
information for the treatment of stimulant use  
disorders – Rong Xu, Ph.D
- Q and A/panel discussion

# 2022-2023: Provisional\* Drug Overdose Deaths

## 12-months ending in select months

	ALL DRUGS	HEROIN	NAT & SEMI SYNTHETIC	METHADONE	SYNTHETIC OPIOIDS (mainly illicit fentanyl)	COCAINE	OTHER PSYCHO-STIMULANTS (mainly meth)
7/2022*	109,416	7,190	12,707	3,443	74,048	26,989	34,724
1/2023*	110,784	5,753	11,917	3,362	76,438	28,607	35,766
7/2023*	111,964	4,768	11,076	3,405	78,287	30,290	36,937
Percent Change 7/22-7/23	2.3%	-33.7%	-12.8%	-1.1%	5.7%	12.2%	6.4%

\*NCHS Provisional drug-involved overdose death counts are PREDICTED VALUES, 12 months ending in select months.  
<https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm>